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Valproic acid (2-propyl pentanoic acid) is a pharmaceutical drug used for treatment of 
epileptic seizures absence, tonic-clonic (grand mal), complex partial seizures, and 
mania in bipolar disorder [1]. Valproic acid is a slightly soluble in water and therefore as 
active pharmaceutical ingredient it is most commonly applied in form of sodium or 
magnesium valproate salt [1].However the list of adverse effects of these compounds is 
large and includes among others: tiredness, tremor, sedation and gastrointestinal 
disturbances [2]. Ionic liquids (ILs) are promising compounds as Active Pharmaceutical 
Ingredients (APIs)[3]. In this context, the combinations of the valproate anion with 
appropriate cation when ILs and salts are formed can significantly alter valproate 
physical, chemical and thermal properties.[4] This methodology can be used for drug 
modification (alteration of drug solubility in water, lipids, bioavailability, etc)[2] and 
therefore can eliminate some adverse effect of the drugs related to drug toxicity due for 
example to its solubility in water and lipids (interaction with intestines). 
Herein, we will discuss the development of ILs based on valproate anion (Figure 1) 
prepared according a recent optimized and sustainable acid-base neutralization 
method [4]. The organic cations such as cetylpyridinium, choline and imidazolium 
structures were selected based on their biocompatibility and recent applications in 
pharmacy [3].  
 
All novel API-ILs based on valproate have been studied in terms of their physical, 
chemical (viscosity, density, solubility) and thermal (calorimetric studies) properties as 
well as their biological activity. 
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